Cisplatin-induced acute renal failure is ameliorated by erdosteine in a dose-dependent manner

Journal of Applied Toxicology

Volumn 24, Issue 4, 2004, Pages 269-275

  Özyurt, Hüseyin ^a   Yildirim, Zeki ^b   Kotuk, Mahir ^b   Yilmaz, H Ramazan ^c   Yaǧmurca, Murat ^d   Iraz, Mustafa ^b   Söǧüt, Sadik ^e   Gergerlioglu, Serdar ^f  

^a GAZIOSMANPASA UNIVERSITY   (Turkey)

^b INONU UNIVERSITY   (Turkey)

^c SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^d AFYON KOCATEPE UNIVERSITY   (Turkey)

^e MUSTAFA KEMAL UNIVERSITY   (Turkey)

^f GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

Cisplatin; Erdosteine; Renal failure

Indexed keywords

CATALASE; CISPLATIN; CREATININE; EOSIN; ERDOSTEINE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HEMATOXYLIN; MALONALDEHYDE; NITROGEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SUPEROXIDE DISMUTASE; UREA;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME ANALYSIS; FEMALE; HISTOPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE SECTION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; BLOOD UREA NITROGEN; CISPLATIN; CREATININE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FREE RADICAL SCAVENGERS; INJECTIONS, INTRAPERITONEAL; KIDNEY; KIDNEY FAILURE, ACUTE; RATS; RATS, WISTAR; THIOGLYCOLATES; THIOPHENES;

EID: 4444225768     PISSN: 0260437X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jat.983     Document Type: Article

References (33)

1. Aebi H. 1974. Catalase. In Methods of Enzymatic Analysis, Bergmeyer HU (ed.) Academic Press: New York; 673-677.
2. Appenroth D, Frob S, Kersten L, Splinter FK, Winnefeld K. 1997. Protective effects of vitamin E and C on cisplatin nephrotoxicity in developing rats. Arch. Toxicol. 71: 677-683.
3. Baliga R, Ueda N, Walker PD, Shah SV. 1999. Oxidant mechanisms in toxic acute renal failure. Drug Metab. Rev. 3: 971-997.
4. Baliga R, Zhang Z, Baliga M, Ueda N, Shah SV. 2001. In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney Int. 53:394-401.
5. Biagi GL Fregnan GB Gazzani G, Vandoni G. 1989. Erdosteine protection from cigarette smoke-induced loss of alpha 1-antitrypsin activity in rat lungs. Int. J. Clin. Pharmacol. Ther. Toxicol. 27: 235-237.
6. Braga PC, Dal Sasso M, Zuccotti T. 2000. Assessment of the antioxidant activity of the SH metabolite I of erdosteine on human neutrophil oxidative bursts. Arzneimittelforschung 50: 739-746.
7. Davis CA, Nick HS, Agarwal A. 2001. Manganese superoxide dismutase attenuates cisplatin-induced renal injury: importance of superoxide. J. Am. Soc. Nephrol. 12: 2683-2690.
8. Dechant KL, Noble S. 1996. Erdosteine. Drugs 52: 875-881.
9. Fadillioglu E, Erdogan H. 2003 Effects of erdosteine treatment against doxorubicin-induced toxicity through erythrocyte and plasma oxidant/antioxidant status in rats. Pharmacol. Res. 47: 317-322.
10. Fadillioglu E, Erdogan H, Sogut S, Kuku I. 2003. Protective effects of erdosteine against doxorubicin-induced cardiomyopathy in rats. J. Appl. Toxicol. 23: 71-74.
11. Giovanni LD, Fregnan GB, Rabitti C, Murari G, Amato A, Sovera A, Civello IM. 1991. Lack of gastric adverse effect of erdosteine in rats and men. Int. J. Clin. Pharmacol. Toxicol. 29: 269-273.
12. Greggi Antunes LM, Darin JD, Bianchi MD. 2000. Protective effects of vitamin C against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats: a dose-dependent study. Pharmacol. Res. 41: 405-411.
13. Hagiwara S, Ishii Y, Kitamura S. 2000. Aerosolized administration of N-acetylcysteine attenuates lung fibrosis induced by bleomycin in mice. Am. J. Respir. Crit. Care. Med. 162: 225-231.
14. Hartmann JT, Kollmannsberger C, Kanz L, Bokemeyer C. 1999. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int. J. Cancer. 83: 866-869.
15. Hayashi K, Hosoe H, Kaise T, Ohmori K. 2000. Protective effect of erdosteine against hypochlorous acid-induced acute lung injury and lipopolysaccharide-induced neutrophilic lung inflammation in mice. J. Pharm. Pharmacol 52: 1411-1416.
16. Johnsson A, Wennerberg J. 1999. Amifostine as a protector against cisplatin-induced toxicity in nude mice. Acta. Oncol. 38: 247-253.
17. Kelly KJ, Meehan SM, Colvin RB, Williams WW, Bonventre JV. 1999. Protection from toxicant-mediated renal injury in the rat with anti-CD54 antibody. Kidney Int. 56: 922-931.
18. Lowry 0, Rosenbraugh N, Farr L, Randall R. 1951. Protein measurement with the Folin-phenol reagent. J. Biol. Chem. 183: 265-275.
19. Mollar AS, Closa D, Cortijo J, Morcillo EJ, Parts N, Gironello M, Panes J. 2002. p-Selectin up-regulation in bleomycin-induced lung injury in rats: effect of N-acetyl-L-cysteine. Thorax. 57: 629-634.
20. Nisar S, Feinfeld DA. 2002. N-Acetylcysteine as salvage therapy in cisplatin nephrotoxicity. Renal Fail. 24: 529-533.
21. Ozen S, Akyol 0, Iraz M, Sogut S, Ozugurlu F, Ozyurt H, Odaci E, Yildirim Z. 2004. The role of caffeic acid phenethyl ester, an active component of propolis, against cisplatin-induced nephrotoxicity in rats. J. Appl. Toxicol. 24:27-35.
22. Ozyurt H, Irmak MK, Akyol 0, Sogut S. 2001. Caffeic acid phenethyl ester changes the indices of oxidative stress in serum of rats with renal ischaemia-reperfusion injury. Cell Biochem. Funct. 19: 259-263.
23. Pagia DE, Valentine WN. 1967. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J. Lab. Clin. Med 70: 158-170.
24. Ricevuti G, Mazzone A, Uccelli E, Gazzani G, Fregnan GB. 1988. Influence of erdosteine, a mucolytic agent, on amoxycillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis. Thorax 43: 585-590.
25. Sueishi K, Mishima K, Makino K, Itoh Y, Tsuruya K, Hirakata H, Oishi R. 2002. Protection by a radical scavenger edaravone against cisplatin-induced nephrotoxicity in rats. Eur. J. Pharmacol. 451: 203-208.
26. Sun Y, Oberley LW Li Y. 1988. A simple method for clinical assay of superoxide dismutase. Clin. Chem. 34: 497-500.
27. Vagliasindi M, Fregman GB. 1989. Erdosteine protection against cigarette smoking-induced functional antiprotease deficiency in human bronchiolo-alveolar structures. Int. J. Clin. Farmacol. ToxicoL 27: 238-241.
28. Walker Jr EM, Gale GR. 1981. Methods of reduction of cisplatin nephrotoxicity. Ann. Clin. Lab. Sci. 11:397-410.
29. Wasowicz W, Neve J, Peretz A. 1993. Optimized steps in fluorometric determination of thiobarbituric acid-reactive substances in serum: Importance of extraction pH and influence of sample preservation and storage. Clin. Chem. 39: 2522-2526.
30. Wei H, Frenkel K. 1993. Relationship of oxidative events and DNA oxidation in SENCAR mice to in vivo promoting activity of phorbol ester-type tumor promoters. Carcinogenesis 14: 1195-1201.
31. Xia Y, Zweier JL. 1995. Substrate control of free radical generation from xanthine oxidase in the postischemic heart. J. Biol 270: 18797-18803.
32. Yildirim Z, Sogut S, Odaci E, Iraz M, Ozyurt H, Kotuk M, Akyol 0. 2003. Oral erdosteine administration attenuates cisplatin-induced renal tubular damage in rats. Pharmacol Res. 47: 149-156.
33. Zhang JG, Viale M, Esposito M, Lindup WE. 1999. Tiopronin protects against the nephrotoxicity of cisplatin in the rat. Hum. Exp. Toxicol. 18: 713-717.